Tuberculosis, Meningeal
Conditions
Keywords
Tuberculous meningitis, Rifampicin, Dose finding study, Pharmacokinetics
Brief summary
Tuberculous meningitis (TBM) is the most severe form of tuberculosis infection with high mortality. Current treatment regimens are not based on clinical trials. Rifampicin is a key drug for TBM, but its penetration into the brain is limited, suggesting that a higher dose may be more effective. There are several highly relevant, outstanding questions related to the appropriate dose of rifampicin for TBM, before a multicenter phase 3 trial can be performed. These are: 1. Previous phase 2a randomized clinical trial (done in the same setting as this proposed study) suggests that high doses of intravenous rifampicin (600mg, circa 13 mg/mg) for TBM is safe and associated with a survival benefit in adults. Given that i.v. rifampicin is not readily available, this needs to be confirmed using an equivalent higher oral dose of rifampicin. 2. Recent pharmacokinetic analysis of a continuation trial comparing 600 mg i.v. rifampicin with 750 mg and 900 mg oral rifampicin suggests that an even higher dose may be needed; but this has not been examined 3. Based on those previous data, there is a need to explore a longer duration of high-dose rifampicin for a subsequent phase 3 randomized clinical trial; treatment response in the investigators previous trial suggest that the optimal duration may be \> 14 days. 4. There is a need to explore relevant treatment endpoints besides mortality including neurological, neuroradiological and inflammatory response.
Interventions
DRUGPlacebo
Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet. Patients receiving 1350 mg rifampicin will not receive any placebo tablet. With this arrangement, every subject will receive 3 tablets of study drugs.
DRUGRifampicin
Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin. Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.
DRUGOther TB drugs
Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months. Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
DRUGAdjuvant dexamethasone
Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
Sponsors
United States Agency for International Development (USAID)
Radboud University Medical Center
Universitas Padjadjaran
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or Female, aged 15 years or above. 2. Clinical suspicion of TBM and CSF/blood glucose ratio \< 0.5. 3. None or less than 3 days of anti-tuberculosis chemotherapy taken for the current infection. 4. Patient or representative (if the patient is incapacitated) is willing and able to give informed consent for participation in the study. 5. Willingness to allow storage of specimens.
Exclusion criteria
Patients may not enter the study if any of the following apply: 1. Liver dysfunction (ALT \> 5 times upper limit); kidney dysfunction (eGFR \< 50 ml/min) 2. Pregnancy or breastfeeding (negative urine pregnancy test for all females of child-bearing age). 3. Confirmed cryptococcus meningitis (LFA), or confirmed bacterial meningitis (microscopy). 4. Rapid clinical deterioration at time of presentation (e.g. signs of sepsis, decreasing consciousness or signs of cerebral oedema, or herniation)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rifampicin concentrations in plasma and cerebrospinal fluid (CSF) | Day 2 (+/- 1) after administration of study drugs | The rifampicin concentrations in plasma are measured from blood samples that are obtained by intensive pharmacokinetic sampling at 6 sampling time points (h0, 1, 2, 4, 8, 12 post dose). CSF rifampicin concentration will be measured using CSF sample taken by means of lumbar puncture at hour 3-6 post dose at the same day of blood sampling. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Grade 3 and 4 and serious adverse events | Within 60 days | Determined by measurement of liver function, hematology, gastrointestinal intolerance and hypersensitivity at days 3, 7, 10, 14, 30, 45, and 60 |
| Mortality | 180 days | — |
| Neurological response | Within 60 days | Neurological responses that show both improvement (e.g. time to resolution of comma, time to fever resolution) and worsening (time to development of neurological deficits) will be measured and recorded at days 3, 7, 30 and 60. |
| Rifampicin concentrations in plasma and CSF at steady-state | Day 10 (+/- 1) after starting treatment with study drugs | The rifampicin concentrations in plasma are measured from blood samples that are obtained by intensive pharmacokinetic sampling at 6 sampling time points (h0, 1, 2, 4, 8, 12 post dose). CSF rifampicin concentration will be measured using CSF sample taken by means of lumbar puncture at hour 3-6 post dose at the same day of blood sampling. |
| Resolution of blood and CSF inflammatory response | 7 days | Inflammatory response will be measured at day 0 and day 7 |
| Sensitivity of GeneXpert for diagnosing TBM | Within 6 weeks | Every CSF sample from patients who come with suspicion of TBM will be inoculated in GeneXpert cartridge and standard culture measures (MODS), and the result will be compared. |
| Neuroradiological response | 60 days | Development of infarction or other complication of TBM will documented by performing and comparing brain MRIs that will be done within the first 5 day and 60 day (+/- 5 days) after randomization |
Countries
Indonesia
Outcome results
None listed